These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26349557)

  • 1. Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk.
    Roerecke M; Sørensen P; Laramée P; Rahhali N; Rehm J
    J Psychopharmacol; 2015 Nov; 29(11):1152-8. PubMed ID: 26349557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
    Palpacuer C; Laviolle B; Boussageon R; Reymann JM; Bellissant E; Naudet F
    PLoS Med; 2015 Dec; 12(12):e1001924. PubMed ID: 26694529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
    Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J
    Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
    J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
    Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
    Palpacuer C; Hammas K; Duprez R; Laviolle B; Ioannidis JPA; Naudet F
    BMC Med; 2019 Sep; 17(1):174. PubMed ID: 31526369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2002; (2):CD001867. PubMed ID: 12076425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
    Aubin HJ; Reimer J; Nutt DJ; Bladström A; Torup L; François C; Chick J
    Eur Addict Res; 2015; 21(3):160-168. PubMed ID: 25832297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
    Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2000; (3):CD001867. PubMed ID: 10908513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies.
    van den Brink W; Aubin HJ; Bladström A; Torup L; Gual A; Mann K
    Alcohol Alcohol; 2013; 48(5):570-8. PubMed ID: 23873853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.